MIAMI, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that it has commenced a public offering, subject to market and other conditions, to offer and sell units, consisting of (i) one share of common stock (or pre-funded warrant in lieu thereof) and (ii) one warrant to purchase one share of common stock.

迈阿密，2023年11月9日（全球新闻网）-Fortress Biotech，Inc。（纳斯达克股票代码：FBIO）（“Fortress”或“Company”），一家创新型生物制药公司，专注于高效收购，开发和商业化或货币化有希望的治疗产品和产品候选人，今天宣布它已开始上市，受市场和其他条件的影响，出售及出售单位，包括（i）一股普通股（或代替其的预先资助认股权证）及（ii）一股购买一股普通股的认股权证。

All of the shares of common stock, pre-funded warrants and accompanying warrants are being offered by Fortress. Certain directors and officers of the Company may participate in the offering. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Fortress提供普通股，预先资助的认股权证和随附认股权证的所有股份。本公司某些董事及高级职员可参与本次发行。产品的最终条款将取决于定价时的市场和其他条件，并且无法保证产品是否或何时完成，或产品的实际规模或条款。

Roth Capital Partners is acting as exclusive placement agent for the offering on a reasonable best-efforts basis. Fortress expects to use the net proceeds from the offering for its operations, including, but not limited to, general corporate purposes, which may include research and development expenditures, clinical trial expenditures, manufacture and supply of product, and working capital.

罗斯资本合作伙伴在合理的最佳努力基础上充当独家发行代理。Fortress希望将所提供的净收益用于其运营，包括但不限于一般公司用途，其中可能包括研发支出，临床试验支出，产品制造和供应以及营运资本。

The securities described above are being offered pursuant to a registration statement on Form S-3 (File No. (333-258145), which was declared effective by the Securities and Exchange Commission (the “SEC”) on July 30, 2021. The offering is being made only by means of a prospectus which is a part of the effective registration statement.

上述证券是根据S-3表格（文件号（333-258145））的注册声明提供的，该声明已于2021年7月30日由证券交易委员会（“SEC”）宣布生效。该产品仅通过作为有效注册声明一部分的IPO进行。

A preliminary prospectus related to the offering will be filed with the SEC on November 9, 2023. .

有关该发行的初步IPO将于2023年11月9日向证券交易委员会提交。